增强PHA-LAK细胞诱导激活新途径的研究  

A New Approach to Enhance the Induction and Activation of PHA-LAK Cells

作　　者：范亚欣[1] 程一櫂[1] 郭连英[1] 王艳[1] 钱振超[1] 

机构地区：[1]大连医科大学免疫学教研室,大连116027

出　　处：《中国肿瘤生物治疗杂志》1998年第1期32-35,共4页Chinese Journal of Cancer Biotherapy

摘　　要：本研究应用PHA、抗CD3单抗(aCD3)和rIL-2共同刺激人外周血单个核细胞(PBMC),诱生、扩增新型抗肿瘤效应细胞PHA-aCD3LAN,并与PHA-LAk和CD3AK细胞在某些生物学特性方面进行了比较,结果表明,PHA、aCD3和IL-2具有协同增强效应、使PHA-aCD3LAK细胞的增殖能力、细胞毒活性、mIL-2Ra的表达水平及对IL-2的利用均高于PHA-LAK和CD3AK细胞;三组效应细胞均为异质性细胞群体,均以CD3^+ CD8^+T细胞为主,而PHA-aCD3LAK的CD8^+细胞百分率高于其它两组细胞.采用PHA-aCD3LAK可进一步提高LAK细胞的数量和活性。A new type of killer cells, named PHA-αCD3LAK, was induced by means of costimulating the peripheral blood mononuclear cells (PBMC) with anti-CD3McAb (αCD3) and rIL-2 after PHA-priming for 48 hours. Some biological characteristics of PHA-αCD3LAK, PHA-LAK and CD3AK were compared. The results showed that PHA-αCD3LAK exhibited some advantages over CD3AK and PHA-LAK in proliferation, cytotoxicity, the expression level of mIL-2R, as well as the utilizing of IL-2, suggesting the synergistic enhancing role of PHA, αCD3 and IL-2. All three groups of effector cells were heterogeneous populations, predominantly CD3 + CD8 + T cells. The CD8 ^(+) cell percentage of PHA-αCD3LAK was higher than that of the other two groups. The application of PHA-αCD3LAK might open a new prospect to clinical therapeutic approach.

关 键 词：肿瘤 LAK细胞 PHA-LAK αCD3 治疗 IL-2 IL-2R 

分 类 号：R730.51[医药卫生—肿瘤]